92 related articles for article (PubMed ID: 26572413)
1. Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Yang YC; Cai J; Yin J; Zhang J; Wang KL; Zhang ZT
Carbohydr Polym; 2016 Jan; 136():782-90. PubMed ID: 26572413
[TBL] [Abstract][Full Text] [Related]
2. miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
Li T; Zhang Y; Meng YP; Bo LS; Ke WB
Pharm Res; 2017 Dec; 34(12):2710-2719. PubMed ID: 29181687
[TBL] [Abstract][Full Text] [Related]
3. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
4. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Li YJ; Dong M; Kong FM; Zhou JP
Int J Pharm; 2015 Jul; 489(1-2):83-90. PubMed ID: 25888801
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.
Kim HM; Kim SA; Park SB; Cho JH; Song SY
Scand J Gastroenterol; 2017 May; 52(5):577-584. PubMed ID: 28110575
[TBL] [Abstract][Full Text] [Related]
6. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
Zhang Z; Niu B; Chen J; He X; Bao X; Zhu J; Yu H; Li Y
Biomaterials; 2014 May; 35(15):4565-72. PubMed ID: 24602567
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
Wang Y; Molin DG; Sevrin C; Grandfils C; van den Akker NM; Gagliardi M; Knetsch ML; Delhaas T; Koole LH
Int J Pharm; 2016 Apr; 503(1-2):150-62. PubMed ID: 26965198
[TBL] [Abstract][Full Text] [Related]
9. The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
Tao C; Lin H; Chen S
Gene; 2014 Nov; 552(1):106-15. PubMed ID: 25219752
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Zheng G; Zhao R; Xu A; Shen Z; Chen X; Shao J
Eur J Pharm Sci; 2018 Jan; 111():492-502. PubMed ID: 29107835
[TBL] [Abstract][Full Text] [Related]
11. Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Wang Z; Zhao K; Zhang Y; Duan X; Zhao Y
Pharm Res; 2019 Aug; 36(10):145. PubMed ID: 31396764
[TBL] [Abstract][Full Text] [Related]
12. Self-Assembled and Self-Monitored Sorafenib/Indocyanine Green Nanodrug with Synergistic Antitumor Activity Mediated by Hyperthermia and Reactive Oxygen Species-Induced Apoptosis.
Wu H; Wang C; Sun J; Sun L; Wan J; Wang S; Gu D; Yu C; Yang C; He J; Zhang Z; Lv Y; Wang H; Yao M; Qin W; Wang C; Jin H
ACS Appl Mater Interfaces; 2019 Nov; 11(47):43996-44006. PubMed ID: 31682099
[TBL] [Abstract][Full Text] [Related]
13. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
14. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
15. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib regulating ERK signals pathway in gastric cancer cell.
Juan LW; En LM; Hao L; Kai HY; Ju H
Environ Toxicol Pharmacol; 2014 Sep; 38(2):438-43. PubMed ID: 25136776
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Sprinzl MF; Reisinger F; Puschnik A; Ringelhan M; Ackermann K; Hartmann D; Schiemann M; Weinmann A; Galle PR; Schuchmann M; Friess H; Otto G; Heikenwalder M; Protzer U
Hepatology; 2013 Jun; 57(6):2358-68. PubMed ID: 23424039
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.
Mieszawska AJ; Kim Y; Gianella A; van Rooy I; Priem B; Labarre MP; Ozcan C; Cormode DP; Petrov A; Langer R; Farokhzad OC; Fayad ZA; Mulder WJ
Bioconjug Chem; 2013 Sep; 24(9):1429-34. PubMed ID: 23957728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]